Laura L Lehman1, Heather J Fullerton. 1. Department of Neurology, Boston Children's Hospital, Boston, MA, USA. laura.lehman@childrens.harvard.edu
Abstract
IMPORTANCE: A prior report showed higher stroke mortality in US black children compared with white children (1979-1998), a disparity likely due in part to sickle cell disease, which leads to a high risk of childhood ischemic stroke. We hypothesized that this disparity has diminished since the publication of the Stroke Prevention Trial in Sickle Cell Anemia (STOP trial) in 1998 demonstrating the efficacy of long-term blood transfusions for primary stroke prevention. OBJECTIVE: To evaluate the demographics and secular trends in mortality from ischemic and hemorrhagic stroke (as a primary cause of death) in US children (<20 years) and determine if there has been a decrease in the disparity between white and black children since the publication of the STOP trial in 1998. DESIGN: We used death certificate data from the National Center for Health Statistics, 1988 through 2007. SETTING: United States. PARTICIPANTS: Children who died in 1988 through 2007 in the United States. INTERVENTION: Publication of the STOP trial. MAIN OUTCOME MEASURES: Incidence rate ratios were calculated as the measure of relative risk. RESULTS: Among 1.6 billion person-years of US children (1988-2007), there were 4425 deaths attributed to stroke, yielding an average of 221 deaths per year; 20% were ischemic; 67%, hemorrhagic; and 12%, unspecified. The relative risk of ischemic stroke mortality for black vs white children dropped from 1.74 from 1988 through 1997 to 1.27 from 1998 through 2007. The ethnic disparity in hemorrhagic stroke mortality, however, remained relatively stable between these 2 periods: black vs white relative risk, 1.90 (1988-1997) and 1.97 (1998-2007). CONCLUSIONS AND RELEVANCE: The excess risk of death from ischemic, but not hemorrhagic, stroke in US black children has decreased over the past decade. This may be related to the implementation of an effective ischemic stroke prevention strategy for children with sickle cell disease.
IMPORTANCE: A prior report showed higher stroke mortality in US black children compared with white children (1979-1998), a disparity likely due in part to sickle cell disease, which leads to a high risk of childhood ischemic stroke. We hypothesized that this disparity has diminished since the publication of the Stroke Prevention Trial in Sickle Cell Anemia (STOP trial) in 1998 demonstrating the efficacy of long-term blood transfusions for primary stroke prevention. OBJECTIVE: To evaluate the demographics and secular trends in mortality from ischemic and hemorrhagic stroke (as a primary cause of death) in US children (<20 years) and determine if there has been a decrease in the disparity between white and black children since the publication of the STOP trial in 1998. DESIGN: We used death certificate data from the National Center for Health Statistics, 1988 through 2007. SETTING: United States. PARTICIPANTS: Children who died in 1988 through 2007 in the United States. INTERVENTION: Publication of the STOP trial. MAIN OUTCOME MEASURES: Incidence rate ratios were calculated as the measure of relative risk. RESULTS: Among 1.6 billion person-years of US children (1988-2007), there were 4425 deaths attributed to stroke, yielding an average of 221 deaths per year; 20% were ischemic; 67%, hemorrhagic; and 12%, unspecified. The relative risk of ischemic stroke mortality for black vs white children dropped from 1.74 from 1988 through 1997 to 1.27 from 1998 through 2007. The ethnic disparity in hemorrhagic stroke mortality, however, remained relatively stable between these 2 periods: black vs white relative risk, 1.90 (1988-1997) and 1.97 (1998-2007). CONCLUSIONS AND RELEVANCE: The excess risk of death from ischemic, but not hemorrhagic, stroke in US black children has decreased over the past decade. This may be related to the implementation of an effective ischemic stroke prevention strategy for children with sickle cell disease.
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690
Authors: Cindy E Neunert; Robert W Gibson; Peter A Lane; Pragya Verma-Bhatnagar; Vaughn Barry; Mei Zhou; Angela Snyder Journal: Am J Prev Med Date: 2016-07 Impact factor: 5.043
Authors: Laura L Lehman; Jane C Khoury; J Michael Taylor; Samrat Yeramaneni; Heidi Sucharew; Kathleen Alwell; Charles J Moomaw; Katrina Peariso; Matthew Flaherty; Pooja Khatri; Joseph P Broderick; Brett M Kissela; Dawn O Kleindorfer Journal: J Child Neurol Date: 2018-04-19 Impact factor: 1.987
Authors: Robert J Adams; Dan T Lackland; Lynette Brown; David Brown; Jenifer Voeks; Heather J Fullerton; Julie Kanter; Janet L Kwiatkowski Journal: Am J Hematol Date: 2016-10-25 Impact factor: 10.047